Sheikh Bahmdan Chair of Evidence-based Healthcare and Knowledge Translation, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
BMC Public Health. 2012 Sep 17;12:792. doi: 10.1186/1471-2458-12-792.
Pre-gestational diabetes mellitus is associated with increased risk for maternal and fetal adverse outcomes. This systematic review was carried out to evaluate the effectiveness and safety of pre-pregnancy care in improving the rate of congenital malformations and perinatal mortality for women with pre-gestational diabetes mellitus.
We searched the following databases, MEDLINE, EMBASE, WEB OF SCIENCE, Cochrane Library, including the CENTRAL register of controlled trials and CINHAL up to December 2011, without language restriction, for any pre-pregnancy care aiming at health promotion, glycemic control and screening and treatment of diabetes complications in women with type I or type II diabetes mellitus. Study design were trials (randomized and non-randomized), cohort and case-control studies.
Of the 2452 title scanned 54 full papers were retrieved of those 21 studies were included in this review. Twelve cohort studies at low and medium risk of bias, with 3088 women, were included in the meta-analysis. Meta-analysis suggested that pre-pregnancy care is effective in reducing congenital malformation, Risk Ratio (RR) 0.25 (95% CI 0.16-0.37), number needed to treat (NNT) 19 (95% CI 14-24), and perinatal mortality RR 0.34 (95% CI 0.15-0.75), NNT = 46 (95% CI 28-115). Pre-pregnancy care lowers glycosylated hemoglobin A1c (HbA1c) in the first trimester of pregnancy by an average of 1.92% (95% CI -2.05 to -1.79). However women who received pre-pregnancy care were at increased risk of hypoglycemia during the first trimester of pregnancy RR 1.51 (95% CI 1.15-1.99).
Pre-pregnancy care for women with pre-gestational type 1 or type 2 diabetes mellitus is effective in improving rates of congenital malformations, perinatal mortality and in reducing maternal HbA1C in the first trimester of pregnancy. Pre-pregnancy care might cause maternal hypoglycemia in the first trimester of pregnancy.
孕前糖尿病与母婴不良结局的风险增加有关。本系统评价旨在评估孕前保健在提高孕前 1 型或 2 型糖尿病妇女先天畸形和围产儿死亡率方面的有效性和安全性。
我们检索了以下数据库,包括 MEDLINE、EMBASE、WEB OF SCIENCE、Cochrane 图书馆,包括 CENTRAL 对照试验登记册和 CINHAL,截止到 2011 年 12 月,不限制语言,以寻找任何旨在促进健康、血糖控制以及筛查和治疗 1 型或 2 型糖尿病患者糖尿病并发症的孕前保健。研究设计为试验(随机和非随机)、队列和病例对照研究。
在扫描的 2452 个标题中,有 54 篇全文被检索到,其中 21 项研究被纳入本综述。12 项队列研究,低和中偏倚风险,3088 名妇女,被纳入荟萃分析。荟萃分析表明,孕前保健可有效降低先天畸形的风险,风险比(RR)0.25(95%置信区间 0.16-0.37),需要治疗的人数(NNT)19(95%置信区间 14-24),围产儿死亡率 RR 0.34(95%置信区间 0.15-0.75),NNT = 46(95%置信区间 28-115)。孕前保健可使妊娠早期糖化血红蛋白(HbA1c)平均降低 1.92%(95%置信区间-2.05 至-1.79)。然而,接受孕前保健的妇女在妊娠早期发生低血糖的风险增加,RR 1.51(95%置信区间 1.15-1.99)。
对患有孕前 1 型或 2 型糖尿病的妇女进行孕前保健可有效提高先天畸形、围产儿死亡率的发生率,并降低妊娠早期母亲的 HbA1C。孕前保健可能导致妊娠早期母亲低血糖。